Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › diltiazem

diltiazem

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of diltiazem

8 trials tracked of diltiazem: 3 in phase 3 or 4.

8Trials tracked
3Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 4 2 Phase 3 1 Phase 1 5
  1. Phase 4 Diltiazem in Jervell and Lange-Nielsen Syndrome Completed
  2. Phase 4 Comparison of Diltiazem and Metoprolol in the Management of Acute Atrial Fibrillation or Atrial Flutter Completed
  3. Phase 3 Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem Completed
  4. Phase 1 A Study of LY2623091 in Healthy Participants Completed
  5. Phase 1 A Study to Estimate the Effect of CYP3A4 Inhibitors (Itraconazole, Diltiazem or Verapamil) on the Pharmacokinetics of Single Dose PF- 00489791 in Healthy Volunteers Completed
  6. Phase 1 A Phase I Study to Assess PK of AZD7986 Alone & With Verapamil, Itraconazole or Diltiazem in Healthy Subjects Completed
Show 2 more trials
  1. Phase 1 Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies Completed
  2. Phase 1 Ability of Late Sodium or Calcium Current Block to Balance the ECG Effects of Potassium Current Block Completed

Showing the 8 most-cited and recently-updated of 8 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Calcium channel blockers cause rare pulmonary toxicity at standard doses but increase risk during overdose
Drug Pipeline Sys. Review
Calcium channel blockers cause rare pulmonary toxicity at standard doses but increase risk during overdose Calcium Channel Blockers Linked to Rare Lung Issues in Overdose
This systematic review examines the incidence and mechanisms of pulmonary toxicity associated with calcium channel blockers (CCBs). While pu…
While calcium channel blockers are generally well-tolerated, some reports link specific types to rare cases of lung fluid buildup.
Frontiers Sep 22, 2026
Retrospective analysis of 41,775 reports identifies signals for cognitive disorders with 50 medications including finasteride and diltiazem
Drug Pipeline Cohort
Retrospective analysis of 41,775 reports identifies signals for cognitive disorders with 50 medications including finasteride and diltiazem Analysis of 50 drugs shows statistical links to cognitive issues in vulnerable groups
This retrospective disproportionality analysis examined 41,775 reports from the FDA, JADER, and WHO VigiAccess databases (2004–2024) involvi…
74% of 50 drugs linked to cognitive issues in reports lack FDA warnings, with signals stronger in vulnerable groups like children and senior…
Frontiers Apr 19, 2026
Apixaban Plasma Levels Elevated in Medicare Patients Taking CYP3A4 and P-gp Inhibitors
Drug Pipeline Cohort
Apixaban Plasma Levels Elevated in Medicare Patients Taking CYP3A4 and P-gp Inhibitors Higher Drug Levels Mean More Bleeding Risk
This pilot cohort study evaluated 35 Medicare patients with atrial fibrillation receiving apixaban 5mg BID.
Taking common heart rhythm drugs with apixaban raises blood levels and increases the risk of serious bleeding that can lead to hospitalizati…
medRxiv Apr 19, 2026